News

The fast track status is for the development of evofosfamide (previously known as TH-302) in combination with gemcitabine to treat these patients. Evofosfamide is an investigational drug which

The study showed the investigational cancer immunotherapy MPDL3280A (anti-PDL1) doubled the likelihood of survival (overall survival [OS]; hazard ratio [HR]=0.47) in people whose cancer expressed the highest levels

EIB has granted the loan facility to support the research and development of novel vaccines against Ebola and other infectious diseases as well as cancer immunotherapies. The loan

Thomas K. Equels, Executive Vice Chairman, states, "European Medicines Agency designation of Ampligen(R)/rintatolimod as an orphan drug is an important achievement in our path seeking commercial approval of

The QIDP and Fast Track designations are for the use of CD101 IV in the treatment of candidemia and invasive candidiasis. The QIDP designation, provided under the Generating

The Company expects patient recruitment in the second Phase 3 trial investigating Fovista in combination with Lucentis to be completed approximately by the end of the third quarter

Previously, Curemark announced the successful results of its FDA Phase III double blinded clinical trial for CM-AT in children ages 3-8 with Autism who had low levels of

OSE CEO Dominique Costantini said: "This collaboration represents a significant step as first licensing and distribution agreement in the business development strategy for OSE Pharma with pharmaceutical companies

Patient enrolment is expected to be initiated shortly in this trial, which allows the company to combine its HS-110 with multiple immune modulating strategies. HS-110 is the company’s